Vanda Pharmaceuticals Inc.
VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment ofā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.40
Price-0.23%
-$0.01
1Y
Price
Market Cap
$260.010m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-62.5%
EBITDA Margin-51.7%
Net Profit Margin-29.6%
Free Cash Flow MarginRevenue
$203.467m
+2.4%
1y CAGR-6.2%
3y CAGR-6.0%
5y CAGREarnings
-$66.937m
-254.2%
1y CAGR-389.2%
3y CAGR-312.1%
5y CAGREPS
-$1.14
-245.4%
1y CAGR-411.4%
3y CAGR-328.8%
5y CAGRBook Value
$486.329m
$624.746m
Assets$138.417m
Liabilities$11.638m
DebtDebt to Assets
1.9%
-0.1x
Debt to EBITDAFree Cash Flow
-$65.907m
-305.7%
1y CAGR-198.9%
3y CAGR-161.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company